Bio Pharma Dive
JANUARY 4, 2024
Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 4, 2024
The next time you make yourself a berry smoothie, you might want to hold off on the banana. Sure, this fruit is full of potassium and makes a drink deliciously thick and creamy, but according to researchers from the University of California Davis (UCD), there’s something in bananas that might overpower the antioxidants in berries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 4, 2024
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
Pharmaceutical Technology
JANUARY 4, 2024
Pfizer Canada has received Health Canada approval for gene therapy Beqvez (fidanacogene elaparvovec) for the treatment of haemophilia B.
Bio Pharma Dive
JANUARY 4, 2024
The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity treatment Zepbound.
Pharmaceutical Technology
JANUARY 4, 2024
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by China Immunotech (Beijing) Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration.
Bio Pharma Dive
JANUARY 4, 2024
The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an “organizational streamlining” to focus resources on prioritiy drug programs.
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Macular Edema.
Bio Pharma Dive
JANUARY 4, 2024
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JANUARY 4, 2024
SP-624 is under clinical development by Sirtsei Pharmaceuticals and currently in Phase II for Major Depressive Disorder.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 4, 2024
Dharwad District Chemists & Druggists Association (DDCDA) is devising strategies to differentiate their service with improved customer experience. These span attention to details like patient education to manage their medication, ensure fair business practices in pricing and dispensing medicines efficiently among others.
Pharmaceutical Technology
JANUARY 4, 2024
BridGene has entered into a strategic partnership and licensing deal with Galapagos for the discovery of drug candidates for oncology targets.
Fierce Pharma
JANUARY 4, 2024
Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Dry (Atrophic) Macular Degeneration.
pharmaphorum
JANUARY 4, 2024
Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.
Pharmaceutical Technology
JANUARY 4, 2024
CB-010 is under clinical development by Caribou Biosciences and currently in Phase I for Follicular Lymphoma.
Outsourcing Pharma
JANUARY 4, 2024
Positive results of a study into the effects of an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS) have been announced by Newron Pharmaceuticals.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
JANUARY 4, 2024
(Amlodipine + indapamide + telmisartan) is under clinical development by George Medicines and currently in Phase III for Hypertension.
Fierce Pharma
JANUARY 4, 2024
Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields. | Even after the heady highs of the COVID era, the CDMO realm remains one of biopharma's buzziest fields. In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry.
Pharmaceutical Technology
JANUARY 4, 2024
Agios plans to file regulatory approval for mitapivat by the end of the year after it met primary endpoint in the Phase III trial.
Pharma Times
JANUARY 4, 2024
Metastatic cancer is estimated to be responsible for 90% of cancer deaths
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
JANUARY 4, 2024
ENYO Pharma has secured €39m Series C funding to advance Vonafexor for the treatment of the kidney disease Alport syndrome.
pharmaphorum
JANUARY 4, 2024
Scientists at Roche and Harvard University have discovered a new class of antibiotic that can kill carbapenem-resistant Acinetobacter baumannii (CRAB), a major public health threat
Pharmaceutical Technology
JANUARY 4, 2024
In a move to drive down customer costs, CVS will replace AbbVie’s blockbuster with more affordable biosimilars.
Outsourcing Pharma
JANUARY 4, 2024
Integrated supplier and service provider to the pharma industry, ACG, has secured a position in the World Economic Forum's prestigious community of Global Lighthouses.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
JANUARY 4, 2024
Daiichi Sankyo Europe (DSE) has amended its existing collaboration with Esperion Therapeutics valued at $125m.
pharmaphorum
JANUARY 4, 2024
Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia, like social withdrawal and apathy, that tend not to respond well to antipsychotic drugs.
Pharmaceutical Technology
JANUARY 4, 2024
IMA-203 is under clinical development by Immatics and currently in Phase II for Rhabdomyosarcoma.
Fierce Pharma
JANUARY 4, 2024
Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio keeps striding forward with its sickle cell disease gene therapy Lyfgenia. | Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio has signed a second outcomes-based reimbursement agreement for its sickle cell gene therapy Lyfgenia.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
349 
Let's personalize your content